Eli Lilly and Company announced plans to open a new Lilly Gateway Labs site in Philadelphia, further expanding its strategy of embedding itself in major life science innovation hubs. The new facility will be located in the Center City district in partnership with life sciences real estate developer Breakthrough Properties. The Philadelphia site will provide early-stage biotech companies with fully equipped lab space and opportunities for strategic scientific engagement with Lilly experts. The goal is to create a collaborative environment that accelerates the discovery and development of next-generation medicines by supporting promising startups. This move marks the fourth U.S. location for Lilly's Gateway Labs, joining existing sites in Boston, San Diego, and South San Francisco. By establishing a presence in Philadelphia, Lilly aims to tap into the city's rich ecosystem of academic medical centers and biotech innovation to fuel its research and development pipeline.
Eli Lilly Expands R&D Ecosystem with New Philadelphia Gateway Labs
LLY
Related News
LLY
Eli Lilly Price Target Raised by Daiwa Securities Amid Strong Performance
LLY
Eli Lilly Stock Declines Amid Broader Market Gains and Valuation Debates
LLY
Eli Lilly Combination Therapy Achieves Superior Skin Clearance and Weight Loss in Phase 3b Psoriasis Trial
LLY
Eli Lilly and CSL Ink Licensing Deal for Anti-Inflammatory Drug
LLY